Skip to main content
Clinical Trials/NCT03727854
NCT03727854CompletedNot Applicable

Effect of Premeal Consumption of Protein-enriched, Dietary Fiber-fortified Cereal Bar on Long-term Glycemic Control in Patients With Type 2 Diabetes

Seoul National University Hospital1 site in 1 country40 target enrollmentStarted: August 27, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
40
Locations
1
Primary Endpoint
Change in HbA1c From Baseline

Study Overview

Brief Summary

The aim of this study is to evaluate the effect of premeal protein-enriched bar in long-term glycemic control in patients with type 2 diabetes mellitus. Glucose levels in subjects who intake premeal protein-enriched bar with dietary modification will be compared to those in subjects who only do the dietary modification.

Detailed Description

Forty subjects with type 2 diabetes will be recruited. Every subject will be randomized in two groups, which are premeal protein bar with dietary modification group and dietary modification only group. The study will be conducted for 12 weeks for each participants. All participants will receive diabetes diet education. Intervention group will consume protein-enriched bar before each meals (at least twice a day) and control group will follow diabetes diet education without other additional supplements. Primary outcome is change of HbA1c from baseline for 12 weeks, and secondary outcomes are changes of fasting blood glucose level, body weight, waist circumference, blood lipid level, HOMA-IR and HOMA-beta from baseline for 12 weeks.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
19 Years to 79 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •BMI 18.5~35 kg/m2
  • •Type 2 diabetes patients
  • •Fasting blood glucose ≥ 126 mg/dl or
  • •HbA1c ≥ 6.5% or
  • •Subjects who were previously diagnosed with type 2 diabetes and who have been treated with lifestyle modification only, oral anti-diabetic drugs or basal insulin.

Exclusion Criteria

  • •HbA1c < 6.5% or > 10%
  • •Subjects using insulin other than basal insulin
  • •Subjects who have newly started or have changed anti diabetic drugs within 3 months
  • •Subjects who are allergic to grains, nuts, legumes and milk
  • •Previous history of gastrointestinal surgery (except for hemorrhoid surgery, appendectomy surgery and hernia surgery)
  • •Subjects with chronic unstable disease
  • •Subjects with cognitive impairments who are not able to follow the study protocol
  • •Females who are pregnant or doing breast feeding
  • •Subjects with Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels of higher than 3 times of upper normal ranges
  • •Subjects with hemoglobin level of less than 10.0 g/dL
  • •Subjects with alcohol addiction or drug abuse

Arms & Interventions

Premeal protein group

Experimental

Premeal protein enriched bar with dietary modification

Intervention: Premeal protein enriched bar (Dietary Supplement)

Dietary modofication only group

Other

Dietary modification only

Intervention: Dietary modification (Behavioral)

Premeal protein group

Experimental

Premeal protein enriched bar with dietary modification

Intervention: Dietary modification (Behavioral)

Outcomes

Primary Outcomes

Change in HbA1c From Baseline

Time Frame: 0 week, 12 weeks

Secondary Outcomes

  • Change in Blood High-density Lipoprotein Level From Baseline(0 week, 12 weeks)
  • Change in Fasting Blood Glucose Level From Baseline(0 week, 12 weeks)
  • Change in Body Weight From Baseline(0 week, 12 weeks)
  • Change in Waist Circumference From Baseline(0 week, 12 weeks)
  • Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) From Baseline(0 week, 12 weeks)
  • Change in Blood Low-density Lipoprotein Level From Baseline(0 week, 12 weeks)
  • Change in Blood Triglyceride Level From Baseline(0 week, 12 weeks)
  • Change in Homeostatic Model Assessment of β-cell Function (HOMA-beta) From Baseline(0 week, 12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Young Min Cho

Professor

Seoul National University Hospital

Study Sites (1)

Loading locations...

Similar Trials